Expanding the role of injectable collagenase clostridium histolyticum for the treatment of active phase Peyronie’s disease

Collagenase clostridium histolyticum (CCH) (Xiaflex^TM) has recently become the mainstay and gold standard of minimally invasive management of Peyronie’s disease. Approved by the FDA in 2013 after phase III studies demonstrated efficacy and safety, collagenase is a popular and promising, albeit expensive treatment option. With the exception of phase II and phase III study data, there is a dearth of published outcomes and safety data. At present, Yang and Bennett’s single-provider, prospectively collected series of 49 patients undergoing Xiaflex injections, is only the second published series cataloging efficacy and safety (1).